SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 4/27/2017 5:57:32 AM - Followers: 187 - Board type: Free - Posts Today: 2

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM
Current Price
Volume:
Bid Ask Day's Range
SureTrader
CVM News: CEL-SCI Corporation Releases Letter to Shareholders 04/24/2017 08:00:00 AM
CVM News: CEL-SCI Scientist Presents at the World Vaccine Congress 04/12/2017 08:30:00 AM
CVM News: Proxy Soliciting Materials (revised) (prer14a) 04/05/2017 06:02:47 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 10:12:10 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 04/04/2017 10:07:50 AM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#11044   Interesting and analytical post, thank you JSonja 04/27/17 05:57:32 AM
#11043   Is it a cup and handle ? yankeesnyc27 04/27/17 02:26:45 AM
#11042   I guess I should just toss out everything warfaretrader 04/26/17 09:34:10 PM
#11041   .11 should read .13. yankeesnyc27 04/26/17 03:31:40 PM
#11040   may be as short as seven weeks yankeesnyc27 04/26/17 02:40:50 PM
#11039   CVM Check out the 20 day/ 30 min INTL 04/26/17 01:35:22 PM
#11038   CUP & HANDLE yankeesnyc27 04/26/17 01:27:23 PM
#11037   Cup and handle on 20 day chart. INTL 04/26/17 10:31:37 AM
#11036   More Eyes Watching CVM $$$ thaier 04/26/17 08:13:46 AM
#11035   I am Buying Stroing and Holdung Strong Foxwoods Man 04/26/17 08:06:32 AM
#11034   YES, for sure, CVM is the Next Biotech thaier 04/26/17 08:03:51 AM
#11033   So you are predicting a 1 for 30 R/S? Foxwoods Man 04/26/17 08:00:39 AM
#11032   CVM $ 3,00 US$ Coming soon $$$$$$$$$$$ thaier 04/26/17 07:57:56 AM
#11031   * * $CVM Video Chart 04-25-17 * * ClayTrader 04/25/17 04:59:26 PM
#11030   This will happen soon $$$ sindram 04/25/17 04:57:55 PM
#11029   Good day but can't get too excited. trickledownfacists 04/25/17 04:28:02 PM
#11028   Right on the mark with this point FM: drkazmd65 04/25/17 10:21:50 AM
#11027   The nature of the beast is that with Foxwoods Man 04/25/17 07:00:51 AM
#11026   I would agree with FM as far as Spideyboy 04/25/17 06:52:14 AM
#11025   Hi Sinity, lightrock 04/24/17 09:47:20 PM
#11024   The placement of this paragraph below could be warfaretrader 04/24/17 07:29:27 PM
#11023   Lake Williams sure is forking over a lot..... trickledownfacists 04/24/17 06:45:05 PM
#11022   Thank you, light sinity 04/24/17 06:38:32 PM
#11021   Reading between the lines lightrock 04/24/17 05:22:15 PM
#11020   Agreed, still risky but not as sure as trickledownfacists 04/24/17 04:44:18 PM
#11019   It might be a good trading play but Foxwoods Man 04/24/17 04:02:17 PM
#11018   Agreed - seems mostly positive, and while understandably drkazmd65 04/24/17 03:51:31 PM
#11017   hope your right, just bought 30000 more. Turney 04/24/17 03:35:55 PM
#11016   Agree. I'm looking for that break out warfaretrader 04/24/17 02:52:23 PM
#11015   I hear that. Would be nice to see stoflat 04/24/17 02:30:28 PM
#11014   I'm expecting a breakout to the upside this warfaretrader 04/24/17 09:38:05 AM
#11013   I'm expecting a breakout to upside this week, warfaretrader 04/24/17 09:31:29 AM
#11012   CEL-SCI Corporation Releases Letter to Shareholders Source: Business Wire The trickledownfacists 04/24/17 09:23:09 AM
#11011   Seems positive to me. trickledownfacists 04/24/17 08:33:45 AM
#11010   wtf, really Geert! sinity 04/24/17 08:30:55 AM
#11009   One could spend time creating complex mathematical equations learning curve 04/21/17 11:03:59 PM
#11008   Cel-SCi & MONEY yankeesnyc27 04/21/17 01:07:10 AM
#11007   Don't sweat it. CVM can raise money at Turney 04/20/17 06:49:43 PM
#11006   BURN RATE yankeesnyc27 04/20/17 04:15:57 PM
#11005   I'd like to ask the cvm guru's here warfaretrader 04/20/17 03:04:25 PM
#11004   Can't hold any gains here. GMONEY4 04/20/17 09:35:33 AM
#11003   Is the study jeopardized yet, due to the sinity 04/19/17 06:54:00 PM
#11002   Sold all my shares for a tiny profit. THEBELGIAN77 04/17/17 12:08:21 PM
#11001   Have you even read the first page of learning curve 04/15/17 03:58:25 PM
#11000   Lol. You said that before. learning curve 04/15/17 03:57:09 PM
#10999   Yup, his numbers are wrong as well. trickledownfacists 04/15/17 12:36:38 PM
#10998   I'm sorry, I can't understand anything you say. Turney 04/15/17 12:13:16 PM
#10997   This was a very clear picture of cvm learning curve 04/15/17 12:55:58 AM
#10996   Edit:They been here awhile. In most, if not learning curve 04/14/17 10:40:04 PM
#10995   I've always liked the fact that CVM keeps Turney 04/14/17 11:57:36 AM
PostSubject